KR810000738B1 - Process for preparing 5-alkoxy picolinic acid ester - Google Patents

Process for preparing 5-alkoxy picolinic acid ester Download PDF

Info

Publication number
KR810000738B1
KR810000738B1 KR7702324A KR770002324A KR810000738B1 KR 810000738 B1 KR810000738 B1 KR 810000738B1 KR 7702324 A KR7702324 A KR 7702324A KR 770002324 A KR770002324 A KR 770002324A KR 810000738 B1 KR810000738 B1 KR 810000738B1
Authority
KR
South Korea
Prior art keywords
group
alkoxy
general formula
acid
picolinic acid
Prior art date
Application number
KR7702324A
Other languages
Korean (ko)
Inventor
다께미 고에다
다께시 쓰루오까
우 이찌 시바다
히로야스 아사오까
스 미쓰구 하지
도오 오사무 이
자와 야스 하루 세끼
우에 시게 하루 이노
다로오 니이다
Original Assignee
나까 가와 다게시
메이지제과 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나까 가와 다게시, 메이지제과 주식회사 filed Critical 나까 가와 다게시
Priority to KR7702324A priority Critical patent/KR810000738B1/en
Application granted granted Critical
Publication of KR810000738B1 publication Critical patent/KR810000738B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)

Abstract

Title compds.[I; R1 = C1-6 lower alkyl; R2 CH(R3)OCOR4 (R3 = H, Me ; R4 = C1-5 lower alkyl, lower alkoxy, phenyl, substituted phenyl, aralkyl), C6H2R6R7R8(R6,R7,R8 = H, lower alkyl, alkoxy, halogen) were prepd. by reaction of II(M = H, metal atom) and III(R5 = C1-5 lower fatty acid, alloyl, aralloyl) such as acyloxyalkylhalide, alkoxyalkylhalide and 3-bromophthalide, or reaction II and IV. Thus, 975mg II(R1 = Bu, M = H) in 20 ml(CH3)2NCHO was reacted with 1.5 g III (X = Cl; R3 = Me; R5 = C4H5) to give 1.38 g I[R2 = C4H5C(Me) (Cl) .

Description

5-알콕시-피콜린산에스테르의 제조법Preparation of 5-alkoxy-picolinate

본 발명은 다음 일반식(6)으로 표시되는 신규의 5-알콕시-핀콜린산에스테르의 제조법에 관한 것이다.The present invention relates to a process for producing novel 5-alkoxy-pincholate esters represented by the following general formula (6).

본 발명의 목적화합물 5-알콕시-피콜린산에스테르는Compound 5-alkoxy-picolinic acid ester of the present invention

[일반식 1][Formula 1]

Figure kpo00001
Figure kpo00001

(식중 R1은 탄소수 1-6의 저급알킬기, M은 수소원자 또는 금속원자를 표시한다)로 표시되는 5-알콕시-피콜린산 또는 그 금속염에To a 5-alkoxy-picolinic acid or a metal salt thereof, wherein R 1 represents a lower alkyl group having 1 to 6 carbon atoms, M represents a hydrogen atom or a metal atom

[일반식 2][Formula 2]

Figure kpo00002
Figure kpo00002

(식중 X는 할로겐원자, R3는 수소원자 또는 메틸기, R5는 탄소수 1-5의 저급 지방산잔기(탄소수는 카르보닐기를 포함하지 아니함), 아로일기, 아탈로일기를 표시한다)으로 표시되는 아실옥시알킬할라이드 또는 알콕시알킬할라이드 또는 3-브로모 프탈리드를 탈산제의 존재하에 반응시키거나, 또는(Wherein X represents a halogen atom, R 3 represents a hydrogen atom or a methyl group, R 5 represents a lower fatty acid residue having 1 to 5 carbon atoms (carbon number does not include a carbonyl group), an aroyl group and an ataloyl group) Oxyalkylhalide or alkoxyalkylhalide or 3-bromo phthalide is reacted in the presence of a deoxidizer, or

[일반식 3][Formula 3]

Figure kpo00003
Figure kpo00003

(R6, R7, R8은 서로 동일하거나 또는 상이하여도 좋은 수소원자, 저급알킬기, 저급알콕시기 또는 할로겐을 표시한다)으로 표시되는 페놀 또는 치환페놀을 축합제의 존재하에 반응시키거나 또는 5-알콕시-피콜린산 또는 그 금속염을 산할로겐나이드화시약과 작용시켜 얻어지는Reacting a phenol or a substituted phenol represented by (R 6 , R 7 , R 8 represents the same or different hydrogen atom, lower alkyl group, lower alkoxy group or halogen) in the presence of a condensing agent, or Obtained by reacting 5-alkoxy-picolinic acid or a metal salt thereof with an acid halogenated reagent

[일반식 4][Formula 4]

Figure kpo00004
Figure kpo00004

(식중 R1은 탄소수 1-6의 저급알킬기를 표시하며, X는 할로겐원자를 표시한다)으로 표시되는 5-알콕시 피콜린산의 산할로겐나이드에Wherein R 1 represents a lower alkyl group having 1 to 6 carbon atoms and X represents a halogen atom.

[일반식 5][Formula 5]

Figure kpo00005
Figure kpo00005

(식중 R3은 수소원자 또는 메틸기, R5는 탄소수 1-5의 저급지방산잔기(탄소수는 카르보닐기를 함유하지 않음), 알로일기, 아랄로일기를 표시한다)로 표시되는 아밀옥시 알카노이라, 알콕시 알카노일 또는 일반식Amyloxy alkanoyl represented by (wherein R 3 is a hydrogen atom or a methyl group, R 5 is a C1-5 lower fatty acid residue (carbon number does not contain a carbonyl group), an aloyl group, an araloyl group), Alkoxy alkanoyl or general formula

Figure kpo00006
Figure kpo00006

(식중 R6, R7, R8은 서로 동일하거나 또는 상이하여도 좋은 수소원자, 저급알킬기, 저급알콕시기 또는 할로겐을 표시한다)로 표시되는 페놀, 치환페놀을 탈산제의 존재하에 반응시킴으로써By reacting a phenol and a substituted phenol represented by (wherein R 6 , R 7 , R 8 represent the same or different hydrogen atoms, lower alkyl groups, lower alkoxy groups or halogens) in the presence of a deoxidizer

[일반식 6][Formula 6]

Figure kpo00007
Figure kpo00007

(R1은 위와 동일하고, R2는 일반식

Figure kpo00008
(R3는 수소 또는 메틸기를 표시하고, R4는 탄소수 1-5에 저급알킬기, 탄소수 1-4의 저급알콕시기, 페닐기, 치환페닐기, 알랄킬기)로 표시되는 아실옥시 알칼기, 알콕시알킬기, 프탈리딜기, 또는 일반식,(R 1 is the same as above, R2 is the general formula
Figure kpo00008
R 3 represents hydrogen or a methyl group, R 4 represents a lower alkyl group having 1 to 5 carbon atoms, a lower alkoxy group having 1 to 4 carbon atoms, a phenyl group, a substituted phenyl group, an allyl group, and the like. Thalidil group, or general formula,

(R6, R7, R8은 위와 동일한 의미를 갖임)로 표시되는

Figure kpo00009
페닐 또는 치환페닐기를 표시한다)를 표시한다)으로 표시되는 5-알콕시-피콜린산에스테르를 얻음으로써 제조된다. 5-알콕시-피콜린산은 본 발명자등에 의해 합성된 신규의 혈압강하제로 의약으로서 유용하다(일본 특원소 51-116641호).(R 6 , R 7 , R 8 have the same meaning as above)
Figure kpo00009
Phenyl or a substituted phenyl group)) to produce a 5-alkoxy-picolinate ester. 5-alkoxy-picolinic acid is a novel blood pressure lowering agent synthesized by the present inventors and the like, and is useful as a medicine (Japanese Patent Application No. 51-116641).

본 발명의 5-알콕시-피콜린사의 에스테르유도체는 그 5-알콕시-피콜린산과 동등내지 그 이상의 약효를 나타내며, 원체의 독성이 경감되어 고혈압증 치료에 유용한 화합물이다.Ester derivatives of the 5-alkoxy-picolinic acid of the present invention are equivalent to or higher than those of the 5-alkoxy-picolinic acid, and the compounds are useful in treating hypertension because the toxicity of the original is reduced.

본 발명의 제조법을 다시 상세히 설명하면, 본 발명의 목적화합물인 5-알콕시-피콜린산에스테르류중에 아세톡시메틸, 이소부틸옥시메틸, 피발로일옥시메틸, 피발로일옥시에틸, 이소바로일옥시에틸, 벤조일옥시에틸, P-메톡시벤조일옥시에틸, 3,4,5-트리메톡시벤조일옥시에틸, 에톡시카르보닐옥시에틸등 아실 옥시알킬에스테르류 및 프탈리딜에스테르, 메톡시메틸에스테르, 메톡시에폭시메틸에스테르는 일반식(1)로 표시되는 5-알콕시-피콜린산 또는 그 금속염에 디메틸포름 아미드 또는 디메틸 설폭사이드등의 용매중에 피리딘트리 에틸아민등 염기의 존재하에 일반식(2)로 표시되는 아실옥시알킬할라이드 또는 3-브로모 프탈리드 또는 알콕시알킬할라이드를 작용시킴으로써 얻어진다.The production method of the present invention will be described in detail again. Among the 5-alkoxy-picolinate esters, which are the target compounds of the present invention, acetoxymethyl, isobutyloxymethyl, pivaloyloxymethyl, pivaloyloxyethyl and isovaloyl Acyl oxyalkyl esters such as oxyethyl, benzoyloxyethyl, P-methoxybenzoyloxyethyl, 3,4,5-trimethoxybenzoyloxyethyl, ethoxycarbonyloxyethyl, phthalidyl esters, and methoxymethyl esters And methoxyepoxymethyl ester are represented by the general formula (2) in the presence of a base such as pyridinetriethylamine in a solvent such as dimethylformamide or dimethyl sulfoxide in 5-alkoxy-picolinic acid represented by the general formula (1) or a metal salt thereof. It is obtained by acting the acyloxyalkyl halide or 3-bromo phthalide or the alkoxyalkyl halide represented by

반응온도는 -20℃∼80℃의 범위로 반응시간은 4-20시간이다.The reaction temperature is in the range of -20 ° C to 80 ° C and the reaction time is 4-20 hours.

아실옥시알킬에스테르류, 알콕시알킬에스테르류는 또 일반식(1)의 5-알콕시-피콜린산에 3염화인, 3취화인, 염화티오닐등의 산할로겐시약을 작용시켜 일반식(4)의 산할로겐화물에 유도하고, 이것을 피리딘 중 또는 트리에틸아민등의 염기 존재하에 벤젠, 클로로포름, 염화메틸렌, 디메틸포름아미드, 디옥산등의 유기용매중에 일반식(5)로 표시되는 아실옥시알카노일 또는 알카노일을 반응시켜도 얻을수가 있다.Acyloxyalkyl esters and alkoxyalkyl esters also react acid-halogen reagents such as phosphorus trichloride, trisulfide, and thionyl chloride with 5-alkoxy-picolinic acid of the general formula (1). Induced by the acid halide of the compound, it is acyloxyalkanoyl represented by the general formula (5) in pyridine or organic solvents such as benzene, chloroform, methylene chloride, dimethylformamide, dioxane in the presence of a base such as triethylamine. Alternatively, it can be obtained by reacting alkanoyl.

반응온도는 -20℃-50℃의 범위로 반응시간은 1-10시간이다.The reaction temperature is in the range of -20 ° C-50 ° C and the reaction time is 1-10 hours.

페닐 및 치환페닐에스테르류는 식(1)의 5-알콕시-피콜린산과 일반식(3)으로 표시되는 페노일 또는 치환페노일을 다시클로헥실카르보디이미드등 축합제의 존재하에, 클로로포름, 디옥산, 디메틸포름아미드, 피리딘등의 유기용매중에서 반응시키든가 또는 일반식(4)의 5-알콕시피콜린산의 산할라이드를 피리딘중 또는 트리에틸아민등의 염기존재하에서 클로로포름, 염화메틸렌, 디메틸포름아미드, 디옥산등의 유기용매 중에 일반식(3)의 페노일 또는 치환페노일과 반응시킴으로서 얻어진다.Phenyl and substituted phenyl esters are 5-alkoxy-picolinic acid of formula (1) and phenoyl or substituted phenoyl represented by formula (3) in the presence of a condensing agent such as multicyclohexylcarbodiimide, chloroform, di Chloroform, methylene chloride, dimethylform are reacted in an organic solvent such as oxane, dimethylformamide, pyridine, or an acid halide of 5-alkoxypicolinic acid of the general formula (4) in pyridine or in the presence of a base such as triethylamine. It is obtained by making it react with the phenoyl or substituted phenoyl of General formula (3) in organic solvents, such as an amide and dioxane.

양자 다같이 반응온도는 통상적으로 0℃-40℃로, 반응시간은 3-10시간이다.In both cases, the reaction temperature is typically 0 ° C-40 ° C, and the reaction time is 3-10 hours.

본 발명의 화합물은 어느 것이나 경구 투여로 혈압강하작용을 나타내며 의약으로써 유용하다.Any compound of the present invention exhibits a blood pressure-lowering effect by oral administration and is useful as a medicine.

자연발증 고혈압 랫트(생후 15-20주령, 투여전혈압 175-190mmHg)를 1군 3마리로 하여 본 발명화합물을 어느것이나 5% 아라비아고무+2% 투인(Tween) 80액에 현탁 혹은 유화시켜 경구 투여하였다.Three spontaneous hypertensive rats (15-20 weeks of age, 175-190 mmHg pre-administration blood pressure) were used in one group, and either the compound of the present invention was suspended or emulsified in 80% solution of 5% Arabian rubber + 2% Tween. Administered.

혈압을 무마취랫트의 꼬리(尾)동맥에 폴리에틸렌 캐시터(Catheter)를 삽입하여 혈압 트란쥬너(일본 광전 MP-24T)를 통해 관혈적(觀血的)으로 폴리그라프(일본 광선 RM-85)상에 기록하였다.Blood pressure was inserted into the tail artery of the anesthesia-free rat by inserting a polyethylene catheter into the polygraph (Japanese ray RM-85) through the blood pressure transjuvener (Japanese photoelectric MP-24T). Recorded in.

그 결과는 다음과 같다.the results are as follow.

Figure kpo00010
Figure kpo00010

본 발명의 화합물의 경구투여로 독성 LD50은 유리산이 300-500mg/kg인데 대해서 아실옥시메틸에스테르류 및 알콕시알킬에스테르류는 600-1000mg/kg 또 프탈리딜에스테르는 약 1200mg/kg으로 원제(原體)에 비하여 어느 것이나 독성은 경감된다.Oral administration of the compound of the present invention, toxic LD50 is 300-500 mg / kg free acid, acyloxymethyl esters and alkoxyalkyl esters are 600-1000 mg / kg and phthalidyl ester is about 1200 mg / kg. In comparison to all the toxicity is reduced.

임상으로 경구투여할경우, 제형은 본 발명화합물에 통상 사용되고 있는 부형제를 첨가한 타브렛 또 캅셀, 혹은 드라이시럽으로 복용되나 경우에 따라서는 피하주사와같은 비경구 투여도 가능하다.In the case of clinical oral administration, the formulations are taken as tablets or capsules with excipients commonly used in the compounds of the present invention, or as dry syrups, but in some cases parenteral administration such as subcutaneous injections is also possible.

또, 다른 생리적으로 활성약제 특히 이뇨강압제와의 복용도 가능하다.It is also possible to take with other physiologically active agents, in particular diuretics.

이하 제조법의 실시예를 예시한다.The example of the manufacturing method is illustrated below.

[실시예 1]Example 1

5-n-부틸옥시-피콜린산 975mg을 디메틸포름아미드 20ml에 용해하고, 여기에 클로로메틸피발레이고 1.5g 및 트리에틸아민 1.4ml를 가하여 실온하에서 6시간 교반하였다.975 mg of 5-n-butyloxy-picolinic acid was dissolved in 20 ml of dimethylformamide, 1.5 g of chloromethyl pivalrayo and 1.4 ml of triethylamine were added thereto, followed by stirring at room temperature for 6 hours.

반응액에 빙수 10ml를 가하여 2시간 방치한후 그대로 농축 건고하였다. 잔사에 초산에틸 80ml를 가하여 pH2의 산성수, 5% 중조수 및 물 각 50ml로 세정하였다.10 ml of ice water was added to the reaction solution, and the mixture was left for 2 hours and concentrated to dryness. 80 ml of ethyl acetate was added to the residue, and the resultant was washed with 50 ml of acidic water, 5% sodium bicarbonate and 50 ml of water.

초산에틸층은 무수황산소오다로 탈수한 다음, 농축하고 높은 진공하에서 건조하여 5-n-부틸옥시-피콜린산의 피발로일옥시메틸에스테르유상물 1.38g을 얻었다.The ethyl acetate layer was dehydrated with anhydrous sodium sulfate, concentrated and dried under high vacuum to obtain 1.38 g of pivaloyloxymethyl ester oil of 5-n-butyloxy-picolinic acid.

본 화합물은 실리카겔박층크로마토그래피(전개용매 : 벤제 : 아세톤=10 : 1)로 Rf0.73에서 단일 스포트를 나타내었다.This compound showed a single spot at Rf 0.73 by silica gel thin layer chromatography (developing solvent: Benze: acetone = 10: 1).

원소분석치 : C62.18%, H7.38%, N4.53%Elemental Analysis Values: C62.18%, H7.38%, N4.53%

분자식 : C16H23NO5로서의 이론치 : C62.13, H7.44, N4.53(%)Molecular Formula: Theoretical as C 16 H 23 NO 5 : C62.13, H7.44, N4.53 (%)

[실시예 2]Example 2

5-n-부틸옥시-피콜린산 980mg을 디메틸포름아미드 25ml에 용해하고, 여기에 3-브로모프탈리이드 1010mg을 가한다음 트리에틸아민 0.8ml를 첨가하여 실온에서 5시간 교반하였다. 반응액에 빙수 5ml를 가하고 2시간 방치한 다음 농축 건고하였다. 잔사에 초산에틸 100ml를 가해 산성수, 10중조수 및 물 각 5ml로 세정하였다.980 mg of 5-n-butyloxy-picolinic acid was dissolved in 25 ml of dimethylformamide, 1010 mg of 3-bromophthalide was added thereto, and 0.8 ml of triethylamine was added thereto, followed by stirring at room temperature for 5 hours. 5 ml of ice water was added to the reaction solution, and the mixture was left for 2 hours and concentrated to dryness. 100 ml of ethyl acetate was added to the residue, and the resultant was washed with 5 ml of acidic water, 10 sodium bicarbonate water and water.

초산에틸층은 무수황산소오다로 탈수한 다음 약 15ml까지 농축하고 3℃로 방치하여 결정을 석출하였다.The ethyl acetate layer was dehydrated with anhydrous sodium sulfate, concentrated to about 15 ml and left at 3 ° C to precipitate crystals.

이것을 여취하여 n-부틸옥시-피콜린산의 프탈리딜에스테르의 백색 침상 결정 1.22g을 얻었다.This was filtered and 1.22g of white needle crystals of the phthalidyl ester of n-butyloxy- picolinic acid were obtained.

본 화합물은 실리카겔박층크로마토그래피(전개용매 : 벤젠 : 아세톤=10 : 1)로 Rf0.58에서 단일스포트를 나타내었다.This compound showed a single spot at Rf 0.58 by silica gel thin layer chromatography (developing solvent: benzene: acetone = 10: 1).

융점 : 137-138℃Melting Point: 137-138 ℃

원소분석치 : C66.08, H5.17, N4.36(%)Elemental Analysis Values: C66.08, H5.17, N4.36 (%)

분자식 : C18H17NO5로서의 이론치 : C66.05, H5.20, N4.28(%)Molecular Formula: Theoretical as C 18 H 17 NO 5 : C66.05, H5.20, N4.28 (%)

[실시예 3]Example 3

5-n-프로필옥시-피콜린산 835mg을 디메틸포름아미드 25ml에 용해하고 여기에 클로로메틸아세테이트 850mg 및 트리에틸아민 1.3ml를 가하여 실온하에 4시간 교반한다.835 mg of 5-n-propyloxy-picolinic acid is dissolved in 25 ml of dimethylformamide, 850 mg of chloromethyl acetate and 1.3 ml of triethylamine are added thereto, followed by stirring at room temperature for 4 hours.

석출하는 트리에틸아민염산염을 여별하고 여액을 약 5ml까지 농축한 다음 초산에틸 100ml 및 물 50ml를 가하고 2N 가성소다로서 pH8.5로 하여 미반응물 및 잔존디메틸포름아미드를 수층으로 이행시킨다.The precipitated triethylamine hydrochloride is filtered off, the filtrate is concentrated to about 5 ml, 100 ml of ethyl acetate and 50 ml of water are added and pH 8.5 as 2N caustic soda is transferred to the aqueous layer with unreacted and remaining dimethylformamide.

초산에틸층은 다시 물 40ml로 2회 세정한다음 무수황산소오다로 탈수하고 농축한다.The ethyl acetate layer was washed twice with 40 ml of water, and then dehydrated with anhydrous sodium sulfate and concentrated.

높은 진공하에 건조하여 5-n-프로필옥시피콜린산의 아세톡시메틸에스테르유상물 1.14g을 얻었다.Drying under high vacuum yielded 1.14 g of acetoxymethyl ester oil of 5-n-propyloxypicolinic acid.

본 화합물을 실리카겔 박층크로마토그래피(전개용매 : 벤젠 : 아세톤=10 : 1)로 Rf 0.43에서 단일 스포트를 나타내었다.The present compound was subjected to silica gel thin layer chromatography (developing solvent: benzene: acetone = 10: 1) to show a single spot at Rf 0.43.

원소분석치 : C57.01, H5.90, N5.51(%)Elemental Analysis Values: C57.01, H5.90, N5.51 (%)

분자식 : C13H14NO5로서의 이론치 : C56.92, H5.93, N5.53(%)Molecular Formula: Theoretical as C 13 H 14 NO 5 : C56.92, H5.93, N5.53 (%)

[실시예 4]Example 4

5-n-부틸옥시피콜린산 975mg을 디메틸포름아미드 20ml에 용해하고, 여기에 α-피발로일옥시에틸클로라이드 1.52g 및 트리에틸아민 1.4ml를 가해 30℃에서 20시간 교반하였다.975 mg of 5-n-butyloxypicolinic acid was dissolved in 20 ml of dimethylformamide, 1.52 g of α-pivaloyloxyethyl chloride and 1.4 ml of triethylamine were added thereto, followed by stirring at 30 ° C for 20 hours.

이하 실시예 3과 동일한 처리를 하여, 얻어진 초산에틸층을 농축하고 결정성의 잔사를 얻었다.The same treatment as in Example 3 below was carried out to concentrate the obtained ethyl acetate layer to obtain a crystalline residue.

이것을 헥산의 혼액에 의해 재결정하여 5-n-부틸옥시피콜린산의 α-피발로일옥시에틸에스테르의 백색침상결정 1.28g을 얻었다.This was recrystallized with the mixture of hexane, and 1.28 g of white needle crystals of (alpha)-pivaloyl oxyethyl ester of 5-n-butyloxy picolinic acid were obtained.

본 화합물은 실리카겔박층 크로마토그래피(전개용매 : 벤젠 : 아세톤=10 : 1)로 Rf 0.77에서 단일스포트를 나타내었다.This compound showed a single spot at Rf 0.77 by silica gel thin layer chromatography (developing solvent: benzene: acetone = 10: 1).

융점 : 67-68℃Melting Point: 67-68 ℃

원소분석치 : C63.12, H7.76, N4.35(%)Elemental Analysis Values: C63.12, H7.76, N4.35 (%)

분자식 : C17H25NO5로서의 이론치 : C63.16, H7.74, N4.33(%)Molecular Formula: Theoretical as C 17 H 25 NO 5 : C63.16, H7.74, N4.33 (%)

[실시예 5]Example 5

5-n-프로필옥시-피콜린산 835mg을 디메틸포름 아미드 20ml에 용해하고, 여기에 브롬메틸이소부틸레이트 1.7g 및 트리에틸아민 1.3ml를 가해 실온으로 10시간 반응시켰다.835 mg of 5-n-propyloxy-picolinic acid was dissolved in 20 ml of dimethylformamide, and 1.7 g of bromine methyl isobutylate and 1.3 ml of triethylamine were added thereto and allowed to react at room temperature for 10 hours.

이하 실시예 1과 동일하게 처리하여 얻어진 초산에틸층을 농축하고 높은 진공하에 건조하여 5-n-프로필옥시피콜린산의 이소프틸옥시에스테르의 유상물 0.92g을 얻었다.The ethyl acetate layer obtained by the same treatment as in Example 1 below was concentrated and dried under high vacuum to obtain 0.92 g of an oily product of isophthyloxyester of 5-n-propyloxypicolinic acid.

본 화합물은 실리카겔 박층크로마토그래피(전개용매 : 벤젠 : 아세톤=10 : 1)로 Rf0.55에서 단일스포트를 나타내었다.This compound showed a single spot at Rf 0.55 by silica gel thin layer chromatography (developing solvent: benzene: acetone = 10: 1).

원소분석치 : C61.13, H7.18, N4.72(%)Elemental Analysis Values: C61.13, H7.18, N4.72 (%)

분자식 : C15H21O5N으로서의 이론치 : C61.02, H7.12, N4.76(%)Molecular Formula: Theoretical value as C 15 H 21 O 5 N: C61.02, H7.12, N4.76 (%)

[실시예 6]Example 6

5-n-부틸옥시피콜린산 975mg을 디메틸포름아미드 30ml에 용해하고 여기에 α-클로로에틸벤조에이트 1.8g 및 트리에틸아민 1.4ml를 가해 35℃에서 15시간 반응시켰다.975 mg of 5-n-butyloxypicolinic acid was dissolved in 30 ml of dimethylformamide, and 1.8 g of α-chloroethylbenzoate and 1.4 ml of triethylamine were added thereto and reacted at 35 ° C for 15 hours.

이하 실시예 3과 동일하게 처리하여 얻어진 초산에틸층을 농축하여 높은 진공하에 건조함으로써 5-n-부틸옥시피콜린산의 α-벤조일옥시에틸에스테르의 유상물 1.14g을 얻었다.The ethyl acetate layer obtained by the same treatment as in Example 3 below was concentrated and dried under high vacuum to obtain 1.14 g of an oily substance of α-benzoyloxyethyl ester of 5-n-butyloxypicolinic acid.

본 화합물은 실리카겔크로마토그래피(전기용매 : 벤젠 : 아세톤=10 : 1)로 Rf0.76에서 단일스포트를 나타내었다.This compound showed a single spot at Rf 0.76 by silica gel chromatography (electric solvent: benzene: acetone = 10: 1).

원소분석치 : C66.51, H6.08, N4.11(%)Elemental Analysis Values: C66.51, H6.08, N4.11 (%)

분자식 : C19H21O5N으로서의 이론치 : C66.47, H6.12, N4.08(%)Molecular Formula: Theoretical as C 19 H 21 O 5 N: C66.47, H6.12, N4.08 (%)

[실시예 7]Example 7

5-n-부틸옥시피콜린산 975mg을 디메틸포름아미드 30ml에 용해하고 여기에 α-이소발레로옥시에틸클로라이드 1.65g 및 트리에틸아민 1.4ml를 가해 40℃에서 15시간 교반하였다.975 mg of 5-n-butyloxypicolinic acid was dissolved in 30 ml of dimethylformamide, 1.65 g of α-isovalerooxyethyl chloride and 1.4 ml of triethylamine were added thereto, followed by stirring at 40 ° C for 15 hours.

이하 실시에 1과 동일하게 처리하여 얻어진 초산에틸층을 농축하였다. 잔사를 헥산 5ml에 용해하고 30℃에서 방치하여 결정이 석출되었다. 이것을 여취하여 높은 진공하에 건조하여 5-n-부틸옥시피콜린산의 α-이소발레로옥시에틸에스텔의 백색결정 920ml을 얻었다.The ethyl acetate layer obtained by following the same procedure as in Example 1 was concentrated. The residue was dissolved in 5 ml of hexane and left at 30 ° C. to precipitate crystals. This was filtered off and dried under high vacuum to obtain 920 ml of white crystals of α-isovalerooxyethyl ester of 5-n-butyloxypicolinic acid.

본 화합물은 실리카겔박층크로마토그래피(전개용매 : 벤젠 : 아세톤=10 : 1)로 Rf 0.78에서 단일스포트를 나타내었다.This compound showed a single spot at Rf 0.78 by silica gel thin layer chromatography (developing solvent: benzene: acetone = 10: 1).

융점 : 54-55℃Melting Point: 54-55 ℃

원소분석치 : C63.08, H7.79, N4.29(%)Elemental Analysis Values: C63.08, H7.79, N4.29 (%)

분자식 : C17H25O5N으로서의 이론치 : C63.16, H7.74, N4.33(%)Molecular Formula: Theoretical as C 17 H 25 O 5 N: C63.16, H7.74, N4.33 (%)

[실시예 8]Example 8

5-n-부틸옥시-피콜린산 975mg을 디메틸포르마미드 20ml에 용해하고 여기에 α-3,4,5-트리메톡시 벤조일옥시에틸클로라이드 2.0g 및 트리에틸아민 1.3ml를 가해 50℃에서 18시간 교반하였다. 이하 실시예 3과 동일한 처리를 하여 얻어진 초산에틸층을 농축하였다. 그다음 농축물 2.9g을 벤젠 4ml에 용해하고 벤젠으로 충진한 실리카겔(100ml) 컬럼에 의해 벤젠-아세톤(30 : 1)으로 전개하여 10ml씩 나누었다.975 mg of 5-n-butyloxy-picolinic acid was dissolved in 20 ml of dimethylformamide, and 2.0 g of α-3,4,5-trimethoxy benzoyloxyethyl chloride and 1.3 ml of triethylamine were added thereto at 50 ° C. Stir for 18 hours. The ethyl acetate layer obtained by the same treatment as in Example 3 below was concentrated. Then, 2.9 g of the concentrate was dissolved in 4 ml of benzene, developed into benzene-acetone (30: 1) by silica gel (100 ml) column filled with benzene, and divided into 10 ml portions.

프랙숀 30-62를 모아 농축한 다음 에틸에테르 10ml에 용해하고 30℃로 방치하여 결정이 석출되었다.Fractions 30-62 were collected, concentrated, dissolved in 10 ml of ethyl ether, and left at 30 ° C to precipitate crystals.

이것을 여취하고 높은 진공하에서 건조하여 5-n-부틸옥시피콜린산의 α-3,4,5-트리메톡시벤조일옥시 에틸에스테르의 결정 2.1g을 얻었다.This was filtered and dried under high vacuum to obtain 2.1 g of crystals of α-3,4,5-trimethoxybenzoyloxy ethyl ester of 5-n-butyloxypicolinic acid.

본 화합물은 실리카겔박층크로마토그래피(전개용매 : 벤젠 : 아세톤=10 : 1)로 Rf 0.61에서 단일스포트를 나타내었다.This compound showed a single spot at Rf 0.61 by silica gel thin layer chromatography (developing solvent: benzene: acetone = 10: 1).

융점 : 80-80.5℃Melting Point: 80-80.5 ℃

원소분석치 : C61.02, H6.21, N3.18(%)Elemental Analysis Values: C61.02, H6.21, N3.18 (%)

분자식 : C22H27O6N로서의 이론치 : C60.97, H6.24, N3.23(%)Molecular Formula: Theoretical as C 22 H 27 O 6 N: C60.97, H6.24, N3.23 (%)

[실시예 9]Example 9

5-n-부틸옥시-피콜린산 3g을 벤젠 30ml에 현탁하여 염화티오닐 8ml을 가하고 70℃에서 3시간 반응시켰다.3 g of 5-n-butyloxy-picolinic acid was suspended in 30 ml of benzene, 8 ml of thionyl chloride was added, and the mixture was reacted at 70 ° C for 3 hours.

반응액은 그대로 농축건고하여 얻어진 잔사에 벤젠 10ml를 가해 재건조하였다.The reaction solution was concentrated to dryness as it was, and 10 ml of benzene was added to the residue, which was dried again.

이 조작은 다시 2회 반복하여 부생한 염화수소 및 아황산가스를 제거 5-n-부틸옥시-피콜린산의 산클로라이드(염산염)을 조성하였다.This operation was repeated twice to remove byproduct hydrogen chloride and sulfurous acid gas to form an acid chloride (hydrochloride) of 5-n-butyloxy-picolinic acid.

이 산클로라이드 1.2g을 벤젠 5ml에 용해하여 빙냉하에 페놀 0.58g 및 트리에틸아민 2.5ml를 벤젠 100ml에 용해한 액에 교반하면서 10분간에 걸쳐 적가하였다.1.2 g of this acid chloride was dissolved in 5 ml of benzene and added dropwise over 10 minutes with stirring to a solution of 0.58 g of phenol and 2.5 ml of triethylamine in 100 ml of benzene under ice cooling.

5-10℃에서 2시간, 실온에서 다시 2시간 반응한후 반응물로 건조하였다.After reacting for 2 hours at 5-10 ° C. and again for 2 hours at room temperature, the reaction mixture was dried.

잔사는 초산에틸 100ml에 취하여 냉각한 pH2의 염산수, pH9의 알칼리수 및 물 각 50ml로 세정하였다.The residue was taken up in 100 ml of ethyl acetate and washed with cooled hydrochloric acid at pH 2, alkaline water at pH 9 and 50 ml of water.

초산에틸층은 무수황산소오다로 탈수후 농축 건조하여 결정성 잔사를 얻는다.The ethyl acetate layer is dehydrated with anhydrous sodium sulfate and concentrated to dryness to obtain a crystalline residue.

에틸에테르, 헥산의 혼액에 의해 재결정하며 5-n-부틸옥시피콜린산의 페닐에스테르의 백색침상 결정 0.98g을 얻었다.Recrystallization was performed by mixing a mixture of ethyl ether and hexane to obtain 0.98 g of white needle crystals of phenyl ester of 5-n-butyloxypicolinic acid.

융점 : 71-72℃Melting Point: 71-72 ℃

원소분석치 : C71.03, H6.14, N5.21(%)Elemental Analysis Values: C71.03, H6.14, N5.21 (%)

분자식 : C16H17NO3로서의 이론치 : C70.85, H6.27, N5.17(%)Molecular Formula: Theoretical as C 16 H 17 NO 3 : C70.85, H6.27, N5.17 (%)

[실시예 10]Example 10

P-에틸페놀 0.55g 및 트리에틸아민 2.2ml를 클로로포름용액 30ml에 용해하여 이것에 실시예 9의 5-n-부틸옥시-피콜린산의 산클로라이드(염산염) 1.1g의 클로로포름용액 10ml를 빙냉하에 적가하였다.0.55 g of P-ethylphenol and 2.2 ml of triethylamine were dissolved in 30 ml of chloroform solution, and 10 ml of a chloroform solution of 1.1 g of an acid chloride (hydrochloride) of 5-n-butyloxy-picolinic acid of Example 9 was dissolved under ice cooling. Added dropwise.

5-10℃에서 2시간 실온에서 다시 3시간 반응후, 반응액을 냉각한 pH2의 염산수, pH9의 알칼리수 및 물 각 20ml로 세정하였다.After reacting again at room temperature for 2 hours at 5-10 ° C. for 3 hours, the reaction solution was washed with cooled hydrochloric acid of pH 2, alkaline water of pH 9 and 20 ml of water.

클로로포름층은 무수황산소오다로 탈수하며 건고후 에틸에테르헥산의 혼액에 의해 결정화하여 5-n-부틸옥시-피콜린산의 P-에틸페닐 에스테르의 백색결정 0.92g을 얻었다.The chloroform layer was dehydrated with anhydrous sodium sulfate, dried and crystallized by a mixture of ethyl ether hexane to obtain 0.92 g of white crystals of P-ethylphenyl ester of 5-n-butyloxy-picolinic acid.

융점 : 67-68℃Melting Point: 67-68 ℃

원소분석치 : C71.92, H7.13, N4.74(%)Elemental Analysis Values: C71.92, H7.13, N4.74 (%)

분자식 : C18H21NO3로서의 이론치 : C72.24, N7.02, N4.68(%)Molecular Formula: Theoretical as C 18 H 21 NO 3 : C72.24, N7.02, N4.68 (%)

[실시예 11]Example 11

P-히드록시 아세토페논 0.69g 및 트리에틸아민 2.5ml를 디클로로메탄 20ml에 용해하고 여기에 실시예 9의 5-n-부틸옥시-피콜린산의 산클로라이드(염산염) 1.25g의 디클로로메탄용액 5ml를 빙냉하게 적가하였다.0.69 g of P-hydroxy acetophenone and 2.5 ml of triethylamine were dissolved in 20 ml of dichloromethane, and 5 ml of dichloromethane solution of 1.25 g of acid chloride (hydrochloride) of 5-n-butyloxy-picolinic acid of Example 9 was added thereto. Was added dropwise ice-cooled.

3-5℃에서 1시간 다시 실온에서 3시간 반응후 실시예 10과 동일한 처리를 하여 5-n-부틸옥시-피콜린산의 P-아세틸페닐에스테르의 백색결정(초산에틸에 의해 결정화) 0.75g을 얻었다.0.75 g of white crystals (crystallized with ethyl acetate) of P-acetylphenyl ester of 5-n-butyloxy-picolinic acid after the same treatment as in Example 10 after reaction at 3-5 ° C. for 3 hours at room temperature. Got.

융점 : 94-96℃Melting Point: 94-96 ℃

원소분석치 : C69.17, H6.01, N4.50(%)Elemental Analysis Values: C69.17, H6.01, N4.50 (%)

분자식 : C18H19NO4로서의 이론치 : C69.01, H6.07, N4.47(%)Molecular Formula: Theoretical as C 18 H 19 NO 4 : C69.01, H6.07, N4.47 (%)

[실시예 12]Example 12

5-n-부틸옥시-피콜린산 3g을 벤젠 30ml에 현탁하고, 염화티오닐 8ml를 가하여 70℃에서 3시간 반응하였다.3 g of 5-n-butyloxy-picolinic acid was suspended in 30 ml of benzene, 8 ml of thionyl chloride was added, and the mixture was reacted at 70 ° C for 3 hours.

반응액을 그대로 농축 건고하여 얻어진 잔사에 벤젠 10ml를 가하여 다시 건조하였다.10 ml of benzene was added to the residue obtained by concentrating and drying the reaction solution as it was, and drying again.

이 조작을 다시 2회 반복하여 부생하는 염화수소 및 아황산가스를 제거, 5-n-부틸옥시-피콜린산의 산클로라이드(염산염)를 조제하였다.This operation was repeated twice again to remove by-product hydrogen chloride and sulfurous acid gas to prepare an acid chloride (hydrochloride) of 5-n-butyloxy-picolinic acid.

다음으로 이 산클로라이드를 벤젠 20ml에 용해하여 빙냉하에서 5-히드록시인단 2.1g 및 트리에틸아민 7.7ml를 함유한 벤젠용액 30ml에 교반하면서 10분간에 걸쳐 적가하였다.This acid chloride was then dissolved in 20 ml of benzene and added dropwise over 10 minutes with stirring to 30 ml of a benzene solution containing 2.1 g of 5-hydroxyindane and 7.7 ml of triethylamine under ice cooling.

5-10℃에서 1.5시간, 다시 실온에서 4시간 반응을 계속한 다음 반응물을 건고하였다.The reaction was continued for 1.5 hours at 5-10 ° C. and 4 hours at room temperature, and then the reaction was dried.

잔사를 초산에틸 100ml에 취하여 냉각한 pH2의 염산수, pH9의 알칼리수 및 물 각 50ml로 세정하엿다.The residue was taken up in 100 ml of ethyl acetate and washed with cooled hydrochloric acid at pH 2, alkaline water at pH 9 and 50 ml of water.

초산에틸층을 무수황산소오다로 탈수한 다음 농축 건고하여 결정성 잔사를 얻었다.The ethyl acetate layer was dehydrated with anhydrous sodium sulfate, and then concentrated to dryness to obtain a crystalline residue.

에틸에테르, 헥산의 혼액에서 재결정하여 5-n-부틸옥시-피콜린산의 5-인다닐에스테르의 결정 4.59g을 얻었다.4.59 g of crystals of 5-indanyl ester of 5-n-butyloxy-picolinic acid were obtained by recrystallization from a mixture of ethyl ether and hexane.

융점 : 58-59℃Melting Point: 58-59 ℃

원소분석치 : C73.28, H6.86, N4.35(%)Elemental Analysis Values: C73.28, H6.86, N4.35 (%)

분자식 : C19H21NO3로서의 이론치 : D73.31, H6.75, N4.50(%)Molecular Formula: Theoretical as C 19 H 21 NO 3 : D73.31, H6.75, N4.50 (%)

Claims (1)

다음 일반식(1)로 표시되는 5-알콕시-피콜린산 또는 그 금속염에 다음 일반식(2)으로 표시되는 아실옥시알킬할라이드 또는 알콕시알킬할라이드 또는 3-브로모프탈리드를 탈산제(脫酸劑)의 존재하에서 반응시키거나 또는 일반식(3)으로 표시되는 페놀 또는 치환페놀을 축합제(縮合劑)의 존재하에서 반응시킴을 특징으로 하는 다음 일반식(6)의 5-알콕시-피콜린산에스테르의 제조법.The acyloxyalkyl halide or alkoxyalkyl halide or 3-bromophthalide represented by the following general formula (2) is deoxidized to 5-alkoxy-picolinic acid or its metal salt represented by the following general formula (1). 5-alkoxy-picolinic acid of the following general formula (6) characterized by reacting in the presence of a compound or reacting a phenol or a substituted phenol represented by the general formula (3) in the presence of a condensing agent. Preparation of esters.
Figure kpo00011
Figure kpo00011
Figure kpo00012
Figure kpo00012
위 식중, R1은 탄소수 1-6의 저급알킬기, R2는 일반식
Figure kpo00013
[여기서 R3는 수소 또는 메틸기, R4는 탄소수 1-5의 저급알킬기, 탄소수 1-4의 저급알콕시기, 페닐기, 치환페닐기, 아랄킬기로 표시되는 아실옥시아릴기, 알콕시알킬기, 프탈리딜기 또는 일반식
Figure kpo00014
In the above formula, R 1 is a lower alkyl group having 1-6 carbon atoms, R 2 is a general formula
Figure kpo00013
[Wherein R 3 is hydrogen or methyl group, R 4 is lower alkyl group of 1-5 carbon atoms, lower alkoxy group of 1-4 carbon atoms, phenyl group, acyloxyaryl group represented by substituted phenyl group, aralkyl group, alkoxyalkyl group, phthalidyl group Or general formula
Figure kpo00014
(여기서 R6, R7, R8은 서로 같거나 달라도 좋은 수소 원자, 저급알킬기, 저급알콕시기 또는 할로겐원자를 나타냄)으로 표시되는 페닐 또는 치환페닐기], R3은 수소원자 또는 메틸기, R5는 탄소수 1-5의 저급방산잔기(탄소수는 카르보닐기를 포함하지 않음), 아로일기, 아랄로일기, R6, R7, R8은 서로 같거나 또는 달라도 좋은 수소원자, 저급알킬기, 저급알콕시기 또는 할로겐원자 M은 수소원자 또는 금속원자, X는 할로겐원자를 나타낸다.Phenyl or substituted phenyl group represented by (wherein R 6 , R 7 , R 8 may represent the same or different hydrogen atom, lower alkyl group, lower alkoxy group or halogen atom), R 3 is hydrogen atom or methyl group, R 5 is carbon number 1-5 lower acid residues (carbon number does not include carbonyl group), aroyl group, arloyl group, R 6 , R 7 , R 8 may be the same or different hydrogen atoms, lower alkyl group, lower alkoxy group or halogen The atom M represents a hydrogen atom or a metal atom, and X represents a halogen atom.
KR7702324A 1977-10-05 1977-10-05 Process for preparing 5-alkoxy picolinic acid ester KR810000738B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7702324A KR810000738B1 (en) 1977-10-05 1977-10-05 Process for preparing 5-alkoxy picolinic acid ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7702324A KR810000738B1 (en) 1977-10-05 1977-10-05 Process for preparing 5-alkoxy picolinic acid ester

Publications (1)

Publication Number Publication Date
KR810000738B1 true KR810000738B1 (en) 1981-06-27

Family

ID=19205033

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7702324A KR810000738B1 (en) 1977-10-05 1977-10-05 Process for preparing 5-alkoxy picolinic acid ester

Country Status (1)

Country Link
KR (1) KR810000738B1 (en)

Similar Documents

Publication Publication Date Title
RU2436790C2 (en) Method for convergent synthesis of calicheamicin derivatives
JPH05503925A (en) New intermediates, their production and applications
KR810000738B1 (en) Process for preparing 5-alkoxy picolinic acid ester
JPH0140033B2 (en)
WO2019135243A1 (en) Methods for preparation of jasmonate compounds
US3803202A (en) Process for the production of 2-cyano-3,4,5,6-tetrahalogenbenzoic acid alkyl esters
EP0051981B1 (en) Esters of n-(4'-hydroxyphenyl)acetamide with 5-benzoyl-1-methylpyrrole-2-acetic acids
SU803859A3 (en) Method of preparing omega-thiopropionamides or their acid-additive salts
JP2003511444A (en) Method for producing COX-2 inhibitor
JP2905931B2 (en) Process for producing optically active 2-cyclopentenones
SU541428A3 (en) Method for producing glycol ethers
SU461510A3 (en) Method for preparing alkylsulfonic acid esters of 1,3,2-oxazaphosphacyclic compounds
US6706884B2 (en) Short synthesis of pyridine-based pharmaceutical intermediates
EP0373950B1 (en) Process for preparing 1,4-bridged cyclohexane carboxylic acid derivatives and their use
JPH09255668A (en) Production of bisoxazolines
EP0087656B1 (en) Process for the preparation of 1-(4-chlorbenzoyl)-5-methoxy-2-methyl-3-indolylacetoxy-acetic acid
SU791752A1 (en) Method of preparing selenophene-3-aldehydes
JPH03123768A (en) Production of bisalkylsofonoxymethyl ethers or bisarylsulfonoxymethyl ethers
KR810000837B1 (en) Process for preparing -lactam antibiotics
JP2558313B2 (en) Dehydration condensing agent and method for producing the same
JP3012933B1 (en) Dithianaphthalenophane compound and method for producing the same
FR2555179A1 (en) New 1-Ä2-carbethoxy-4-(furyl- or benzofurylcarboxamido)phenoxyÜ-3-amino-2-propanols: their preparations and their applications in therapeutics
JPH03178959A (en) Production of bisalkylsulfonomethyl ethers or bisarylsulfonoxymethyl ethers
KR890001851B1 (en) Process for the preparation of amine alkanolester
JP3669726B2 (en) Process for producing optically active 3- (p-alkoxyphenyl) glycidic acid ester derivative